Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 7 |
| List of Tables | 7 | 1 |
| List of Figures | 8 | 1 |
| Introduction | 9 | 1 |
| Global Markets Direct Report Coverage | 9 | 1 |
| Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) Overview | 10 | 1 |
| Therapeutics Development | 11 | 5 |
| Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) Products under Development by Stage of Development | 11 | 1 |
| Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) Products under Development by Therapy Area | 12 | 1 |
| Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) Products under Development by Indication | 13 | 3 |
| Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) Pipeline Products Glance | 16 | 2 |
| Late Stage Products | 16 | 1 |
| Early Stage Products | 17 | 1 |
| Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) Products under Development by Companies | 18 | 6 |
| Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) Products under Development by Universities/Institutes | 24 | 2 |
| Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) Therapeutics Assessment | 26 | 7 |
| Assessment by Monotherapy/Combination Products | 26 | 1 |
| Assessment by Mechanism of Action | 27 | 2 |
| Assessment by Route of Administration | 29 | 2 |
| Assessment by Molecule Type | 31 | 2 |
| Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) Companies Involved in Therapeutics Development | 33 | 15 |
| Advaxis, Inc. | 33 | 1 |
| American Gene Technologies International Inc. | 34 | 1 |
| Aprea AB | 35 | 1 |
| Cellceutix Corporation | 36 | 1 |
| Critical Outcome Technologies Inc. | 37 | 1 |
| Eleos Inc. | 38 | 1 |
| ORCA Therapeutics B.V. | 39 | 1 |
| OSE Immunotherapeutics | 40 | 1 |
| PCI Biotech Holding ASA | 41 | 1 |
| Quark Pharmaceuticals, Inc. | 42 | 1 |
| Shenzen SiBiono GeneTech Co., Ltd. | 43 | 1 |
| SK Biopharmaceuticals Co., Ltd. | 44 | 1 |
| Stemline Therapeutics, Inc. | 45 | 1 |
| Tara Immuno-Oncology Therapeutics LLC | 46 | 1 |
| Z53 Therapeutics, LLC | 47 | 1 |
| Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) Drug Profiles | 48 | 59 |
| Adxs-LmddA159 Drug Profile | 48 | 2 |
| AG-1101 Drug Profile | 50 | 1 |
| APR-017 Drug Profile | 51 | 1 |
| APR-246 Drug Profile | 52 | 3 |
| ATRN-502 Drug Profile | 55 | 1 |
| cenersen sodium Drug Profile | 56 | 1 |
| contusugene ladenovec Drug Profile | 57 | 3 |
| COTI-2 Drug Profile | 60 | 8 |
| D-12PGJ3 Drug Profile | 68 | 1 |
| Gene Therapy to Activate p53 for Head and Neck Squamous Cell Carcinoma Drug Profile | 69 | 1 |
| Gene Therapy to Activate p53 for Oncology Drug Profile | 70 | 1 |
| KM-3174 Drug Profile | 71 | 11 |
| MHY-449 Drug Profile | 82 | 1 |
| MJ-05 Drug Profile | 83 | 1 |
| MX-225 Drug Profile | 84 | 1 |
| N-2 Drug Profile | 85 | 1 |
| Oncolytic Viruses to Activate p53 for Oncology Drug Profile | 86 | 1 |
| OSE-2101 Drug Profile | 87 | 3 |
| p28 Drug Profile | 90 | 2 |
| QPAL-1 Drug Profile | 92 | 1 |
| QPI-1002 Drug Profile | 93 | 3 |
| Recombinant Protein to Activate p53 for Oncology Drug Profile | 96 | 1 |
| SGT-53 Drug Profile | 97 | 2 |
| SL-801 Drug Profile | 99 | 2 |
| Small Molecule to Target Cdk2, Cdk4, Cdk6, Cyclin D1, Cyclin B1, Cdc2, p53 and p16 for Bacterial Infections and Oncology Drug Profile | 101 | 1 |
| Small Molecules to Activate p53 for Melanoma Drug Profile | 102 | 1 |
| Small Molecules to Activate p53 for Oncology Drug Profile | 103 | 1 |
| Small Molecules to Activate p53 for Oncology and Viral Infections Drug Profile | 104 | 1 |
| Vaccine to Target Cellular Tumor Antigen p53 for Oncology Drug Profile | 105 | 1 |
| ZMC-1 Drug Profile | 106 | 1 |
| Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) Dormant Projects | 107 | 7 |
| Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) Discontinued Products | 114 | 1 |
| Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) Featured News &Press Releases | 115 | 11 |
| Aug 03, 2016: Cellceutix Prepares Phase 2a Ovarian Cancer Trial of Kevetrin, a Novel p53-Modulating Drug Candidate, Based Upon Phase 1 Topline Data | 115 | 1 |
| Jul 12, 2016: Critical Outcome Initiates Third Cohort in Phase 1 Study of COTI-2 in Gynecologic Cancers | 116 | 1 |
| Jun 06, 2016: Critical Outcome Activates Second Clinical Trial Site for Its COTI-2 Gynecological Cancer Study | 116 | 1 |
| Jun 06, 2016: Cellceutix Announces Database Lock in Phase 1 Trial of Kevetrin, a Promising New Cancer Treatment That Activates p53 | 117 | 1 |
| Jun 06, 2016: Aprea AB Announces Efficacy and Safety Data in High-Grade Serous Ovarian Cancer Patients Treated with Investigational APR-246 Presented at 2016 ASCO Annual Meeting | 118 | 1 |
| Jun 06, 2016: Cancer drug trial success | 119 | 1 |
| May 24, 2016: Critical Outcome Receives Additional Patent Protection for Potential Transformational P53 Cancer Treatment | 120 | 1 |
| May 03, 2016: Stemline Therapeutics Clears First Cohort of Patients in Ongoing SL-801 Phase 1 Trial | 120 | 1 |
| Apr 27, 2016: Critical Outcome Technologies Augments Advisory Board Drug Development Experience | 120 | 1 |
| Apr 19, 2016: Critical Outcome Commences Treatment of Second Cohort in Phase 1 Study of COTI-2 in Gynecologic Cancers | 121 | 1 |
| Mar 31, 2016: Cellceutix Successfully Completes In Vitro Study in Support of Planned Phase 2 Trial of Kevetrin for Ovarian Cancer | 122 | 1 |
| Mar 14, 2016: Quark Pharmaceuticals Doses First Patient In Two Pivotal Clinical Studies of RNAi-Based Therapeutic QPI-1002 | 123 | 1 |
| Feb 22, 2016: Assay Results From Cellceutix Phase 1 Clinical Trial of Kevetrin for Cancer Show Increased p21 Expression in 67.5% of Evaluable Patients | 123 | 1 |
| Feb 22, 2016: First patients enrolled and dosed in the pivotal trial of Phase 3 of the immunotherapy Tedopi for advanced non-small cell lung cancer | 124 | 1 |
| Feb 16, 2016: Critical Outcome Treats First Patient in Phase 1 Study of COTI-2 in Gynecologic Cancers | 125 | 1 |
| Appendix | 126 | 2 |
| Methodology | 126 | 1 |
| Coverage | 126 | 1 |
| Secondary Research | 126 | 1 |
| Primary Research | 126 | 1 |
| Expert Panel Validation | 126 | 1 |
| Contact Us | 126 | 1 |
| Disclaimer | 127 | 1 |
